Table 2.

Incidence of bleeding events during the treatment period ^a

	MiRI	SRI
	Edoxaban 30 mg	Edoxaban 15 mg			Fondaparinux 1.5 mg
CL CR mL/min	≥50 to ≤80	≥15 to <30	≥15 to <20	≥20 to <30	≥20 to <30
N	30	29 (total)	7	22	20
Any bleeding events
n (%)	10 (33.3)	6 (20.7)	1 (14.3)	5 (22.7)	8 (40.0)
95% CI b	19.2, 51.2	9.8, 38.4	2.6, 51.3	10.1, 43.4	21.9, 61.3
Major or CRNM bleeding
n (%)	2 (6.7)	1 (3.4)	0	1 (4.5)	1 (5.0)
95% CI b	1.8, 21.3	0.6, 17.2	0.0, 35.4	0.8, 21.8	0.9, 23.6
Major bleeding
n (%)	0	0	0	0	0
95% CI b	0.0, 11.4	0.0, 11.7	0.0, 35.4	0.0, 14.9	0.0, 16.1
CRNM bleeding
n (%)	2 (6.7)	1 (3.4)	0	1 (4.5)	1 (5.0)
95% CI b	1.8, 21.3	0.6, 17.2	0.0, 35.4	0.8, 21.8	0.9, 23.6
Minor bleeding
n (%)	10 (33.3)	5 (17.2)	1 (14.3)	4 (18.2)	7 (35.0)
95% CI b	19.2, 51.2	7.6, 34.5	2.6, 51.3	7.3, 38.5	18.1, 56.7

CI = confidence interval; CRNM = clinically relevant non-major; MiRI = mild renal impairment; SRI = severe renal impairment.

^aSafety analysis set; ^bScore method.